Latest / Psychopharmacology Today / Ep. 5: So You Want to Be a Prescribing Psychologist?
Transcript
- 0:05Well, welcome everyone to Psychopharmacology.
- 0:08We are here with our very esteemed Dr.
- 0:12George Kapalka.
- 0:14He has graciously allowed us his time to talk a little bit more about his experiences and his training in psychopharmacology.
- 0:26But let me go ahead and dive into this bio just a little bit.
- 0:30It's really impressive.
- 0:32So Dr.
- 0:32Kapalka holds a PhD in clinical psychology and a master's in clinical psychopharmacology.
- 0:40He's board-certified in clinical psychology and is a fellow of the American Psychological Association's Divisions 53 and 55.
- 0:50Over 20 years, he's led a private mental health clinic in New Jersey
- 0:54that primarily focuses on the assessment and treatment of children and adolescents with learning and emotional problems.
- 1:01He's a certified school psychologist and he's led state-listed independent child study teams that provided assessment and consultation services for various school districts.
- 1:13Trained in psychopharmacology since the early 2000s, Dr.
- 1:17Kapalka has frequently consulted with pediatricians about the use of medication in the treatment of
- 1:22children and adolescents, which, Dr.
- 1:25Kapalka, is one of the things we just recently talked about in the class, some of the challenges and specifically looked at a documentary that came out in 2008 and then the
- 1:35follow-up called "The Medicated Child." And so, very interested in a little bit about what you have to say around pediatrics and medication management as well.
- 1:47Since moving to New Mexico and becoming
- 1:49a prescribing psychologist, Dr.
- 1:52Kapalka is based at CTC Mental Health Services in Albuquerque.
- 1:57In addition to all of the clinical work, he has taught for a year or two or 30, graduate students and developed master's programs in New York and New Jersey.
- 2:09And he is currently the program director and department chair and distinguished professor
- 2:15at Alliant International University's California School of Professional Psychology in our MS in Clinical Psychopharmacology program.
- 2:24He has authored and edited six books and many other forms of publications and his book, "Parenting Your Out of Control Child," has been translated into 10 different languages.
- 2:39His research continues to focus on the psychological, pharmacological, and combined treatments of pediatric disorders.
- 2:46And we are incredibly thrilled to have you and all your wisdom with us this evening.
- 2:53So thank you, Dr.
- 2:54Kapalka.
- 2:56And so I guess what I'd like to do is just start off with asking a little bit more about what inspired your interest in training in psychopharmacology?
- 3:07Thank you.
- 3:08I enjoy speaking about this topic because it's a relatively new direction for psychologists to go into psychopharmacology, something that I became interested in just
- 3:25about 30 years ago in the 1990s.
- 3:27I had always had an interest in child and adolescent
- 3:35psychology, clinical work with kids, teens, and families.
- 3:42And my background in medications was not very strong when I was originally getting my training.
- 3:48Didn't have really very much exposure to it at all.
- 3:52But as I became a psychologist, I started to work more and more with kids and teenagers who were on medications.
- 3:58So I started to have more interest about that.
- 4:01I took some continuing education courses in the 90s to learn a little bit more about it.
- 4:07And then the prescriptive movement for psychologists really started in the 1980s with the first state trying it at the time, which was Hawaii, it failed, but it started to wake up
- 4:22this interest among psychologists saying that, you know, if we get some additional training in medicine and psychopharmacology specifically,
- 4:31adding it to our existing training as psychodiagnosticians and psychotherapists and our knowledge of psychological theories and approaches and developmental theories and all
- 4:44that.
- 4:45Adding it to some medical knowledge would prepare as well to have all the tools kind of in our toolbox where we can intervene when necessary, we can do
- 4:57an in-depth psychological assessment to clarify diagnosis and treatment needs.
- 5:01But then when we intervene for those cases where it's appropriate, psychotherapy, family therapy, various modalities.
- 5:10But for those cases where in addition, some medications can be helpful, we could do that,
- 5:16right? So there was actually a group
- 5:18of... what grew to about 300 psychologists across the
- 5:23that were interested in it and started to complete some of the early training that was being formed around the country at that time.
- 5:35And it was really part of that whole movement that actually Alliant started its MSCP.
- 5:42Most people don't know that actually the Master of Science in Clinical Psychopharmacology at Alliant, CSPP back then, there was no Alliant yet.
- 5:53So the one at CSPP actually was the first in the country.
- 5:57And that started the entire movement.
- 6:00And actually the first couple of classes of students that graduated with that degree went on to become prescribing psychologists in Louisiana, which is what the program was
- 6:12originally formed to do.
- 6:13And then, of course, we had New Mexico and Louisiana as the first two states.
- 6:17Now we have seven states that allow prescriptive authority.
- 6:21So it was really since that time that I had a lot of interest in psychopharmacology.
- 6:29I had practiced in New Jersey until about 2017, which is when I moved to New Mexico.
- 6:37So I had completed the training and I did a lot of consultation with prescribers, with pediatricians on medication needs for kids while I was in New Jersey.
- 6:48I was not prescribing at the time.
- 6:50But then when I moved here in 2017, I became a prescribing psychologist.
- 6:55That is so fascinating.
- 6:56So there are seven states currently that allow for prescribing psychologists.
- 7:02That is...
- 7:03that's interesting.
- 7:04And Alliant was the first to
- 7:07Alliant was the first!
- 7:08We were leading the way!
- 7:11I love that.
- 7:12I love that.
- 7:13So, you know, I can only imagine some of your experience, especially early on in your work.
- 7:20So I'm curious, what are some of the unique aspects that you've experienced in prescribing specifically for the pediatric population?
- 7:29That just seems to be one that we were really struggling with as a class, you know, all the complexity of prescribing to pediatrics.
- 7:39So, know, I think pediatric psychopharmacology has a few challenges.
- 7:47The first challenge is the availability of psychotropic medications for that population.
- 7:57So of course, in the US, we have a large number of psychotropic medications, a lot of different antidepressants, we have medications for ADHD, medications for anxiety, we
- 8:08have...
- 8:08psychotics, mood stabilizers, we have all these different categories of medications, but actually very few of them, with the exception of ADHD, which is an exception to what I'm
- 8:18about to say, but other than that area, there are actually few psychotropics which are specifically FDA-approved for use in the pediatric population.
- 8:31So the vast majority of medications used in the pediatric population are used what we call "off-label." What it means is that the medication was brought to market and approved for
- 8:45psychiatric use for a different population, usually adults.
- 8:49And it is legal to prescribe it now to children, but it's really up to the conscience of each prescriber
- 8:58to decide whether or not, in addition to its FDA indication for adults, does that medication, One: have enough research-based results to suggest that it might be effective
- 9:13in the pediatric population?
- 9:15And Two: that the safety is such that now prescribing this medication to children and adolescents instead of adults,
- 9:25would that still continue to be safe or are we potentially risking some additional problems and side effects that are not yet reported in the literature?
- 9:37So those are really the main challenges that have to do with the fact that so many medications prescribed to the pediatric population are prescribed off-label.
- 9:50And now some of those, even though they're...
- 9:53because you see a lot of that has to do really with politics and finances.
- 9:59So a pharmaceutical company really does not have to go for a second indication.
- 10:06Once it already has a medication on the market, now approve it for something else so that it can be...
- 10:12you know, the only benefit for, for
- 10:16pharmacological, you know, for a pharmaceutical company to do that is that the only advertisement that's permitted for a medication is for the FDA-approved label.
- 10:30So any medication used off-label can not be advertised as being used for that purpose.
- 10:37So that really would be the only benefit for a pharmaceutical company to go back to the FDA and say,
- 10:44We have this medication approved for depression in adults.
- 10:47Now we wanna have it approved in, let's say, pediatrics ages nine through 17, right?
- 10:54So on the one hand, yes, perhaps it would open up another potential population for that pharmaceutical company.
- 11:01On the other hand, the costs of getting another FDA indication are so substantial.
- 11:09And the research requirements are relatively onerous in terms of just how much stuff has to be submitted to the FDA to receive that.
- 11:17But to be honest with you, most companies don't bother.
- 11:21So then we have a drug that's available on the market, safety and efficacy has been approved for adults and has been established.
- 11:29But now we're using it with children and adolescents for a use that is not officially endorsed
- 11:38or approved by the FDA.
- 11:40Now, in some of these cases, these medications from the research that has come out after the medication has been on the market, in some cases, there is very extensive research
- 11:52base of some medications, even though they're not approved for kids, really working pretty well for kids and being safe.
- 12:00In other cases, that's speculative.
- 12:03And so each pediatric prescriber has to be aware
- 12:07of the research base to be able to determine whether or not any given medication is safe and effective, potentially, for use with the pediatric population.
- 12:19So you had talked about some of the unique barriers in terms of politics and funding and whatnot.
- 12:26And I am just curious, are you seeing currently, with the changes in administration and some of the...
- 12:33especially around research, I'm just curious if you've seen anything trickle down to the pharmaceutical field that you are familiar with.
- 12:44So the changes, and hopefully some of them will not go through in their intended version.
- 12:56We've already seen, thankfully, some pushback.
- 13:01For example, when it came to the cuts that were proposed for the National Institutes of Health.
- 13:08Right?
- 13:09So thankfully that's still being debated and hopefully the cuts, if any, will not be nearly as extensive as they proposed.
- 13:18So there's really two prongs to this, probably more, but two that come to mind immediately.
- 13:25One is the research itself.
- 13:27And of course, if you stop funding research, you stop new developments.
- 13:35Mm-hmm.
- 13:36That's not only relevant to psychotropics, that's even more relevant to diseases which still have relatively few cures or treatments, like cancers, some heart diseases,
- 13:53diabetes, some dementias.
- 13:59So a lot of these diseases, just some treatments available for them.
- 14:04But of course,
- 14:05we're far from being able to cure these diseases, right?
- 14:10So the concern is that if research funds start drying up, how much research and development will be able to be done to continue to propel progress that we all hope to
- 14:21have?
- 14:22And, you know, to be honest, America really should be concerned about being competitive with the rest of the world.
- 14:33And if we start eliminating funding for research in the United States, researchers and companies, they're going to go elsewhere.
- 14:45Right?
- 14:46China already actually has made a statement that, with the U.S.
- 14:53now not being so welcoming to foreign scholars, that's fine.
- 14:58our doors.
- 15:00Come on down, we're ready for you, right?
- 15:03So that is a dynamic that unfortunately in America is not being thought about enough, because we might be losing our competitive edge there.
- 15:14What I'm even more concerned about is that with the current cuts that they're talking about,
- 15:25what is going to be impacted is healthcare.
- 15:29Healthcare insurance, healthcare coverage, the availability of treatments of all different sorts will be diminished.
- 15:41And which portions of the populations are going to be affected first?
- 15:45The poorest and the most needy, the most underserved, the ones that already have the most difficulties with access.
- 15:54So if we now eliminate so much funding for Medicaid, what's going to occur with all these people who rely on Medicaid for their healthcare?
- 16:06This is a significant problem.
- 16:08I'm in New Mexico, and New Mexico is one of the states in the country with the highest proportion of the population being covered by Medicaid.
- 16:17So all of a sudden, and of course the federal funds have been
- 16:24crucially important to us to be able to continue to do that.
- 16:28So now if that dries out, what do we do with all these people?
- 16:32And a lot of these people are kids and adolescents because a lot of Medicaid is assistance to families which need additional support to get health coverage for their children.
- 16:46So a lot of these kids and adolescents are going to go without coverage.
- 16:49This pertains to medications in a number of ways and in some ways that we don't really think about, but I think we should.
- 16:58So we already have a problem that those portions of the population which are underinsured, meaning they have health coverage, but the availability of treatments is very limited,
- 17:13when these people have mental health needs,
- 17:18what do they get?
- 17:19Do they get medications or do they get psychotherapy?
- 17:23They get medications because medications are cheaper and a provider can see them once or twice a year to refill their scripts.
- 17:32They don't need weekly sessions.
- 17:35So now, we already see that in this country.
- 17:39There's actually trends and you see that in Medicaid.
- 17:42You see that especially in foster care.
- 17:45Foster care kids are medicated at five times the rates of non-foster care children.
- 17:53The main reason for that is availability of other types of treatments.
- 18:02So now we're going to even more so push, especially the more needy and the more underserved portions of the population,
- 18:14to receive nothing but medications, if that, because everything else is going to be pretty much taken off the table.
- 18:21So it's those kinds of factors that really drive some of the trends.
- 18:27And that's one reason why in the US we medicate children many times more so than we do in other countries, like in European countries.
- 18:37Why?
- 18:38Because their healthcare system is such that psychotherapy services
- 18:43are covered with parity for medical treatments and medication treatments.
- 18:48Therefore, they don't need to make this choice given their availability of their healthcare coverage.
- 18:55They don't even have to think about healthcare coverage because so many of these countries have nationalized healthcare.
- 19:00So that's not even a decision they have to make, right?
- 19:03They just know that, as availability of treatments, that's one of the treatments they can choose.
- 19:10And many families,
- 19:12having that kind of a choice for their kids and adolescents, they do choose psychotherapy.
- 19:17In the United States, that's an additional obstacle, which drives the prescription rates for psychotropic medications for the pediatric population.
- 19:25Wow.
- 19:26So that's a very interesting angle that I know I hadn't thought about in terms of the impact of some of these cuts and reorganizations with respect to the psychopharmacology.
- 19:42I was thinking accessibility, but now we're also talking about choices.
- 19:47Right.
- 19:48Choices.
- 19:48Absolutely.
- 19:49What type of treatment?
- 19:51Interesting.
- 19:52These are clinical counselors that are in this program, and part of the role of this course is to educate the students so that they can better serve with medication monitoring
- 20:07and collaboration with the physicians and the prescribing provider.
- 20:12What kind of things would you advise these students?
- 20:17What kind of things have you seen that it's helpful, not helpful?
- 20:21We really would appreciate any tips you have for them.
- 20:25So let's start with the first point of contact with a prescriber, which would be at the point of a referral.
- 20:35One thing that non-prescribing mental health professionals, I think, need to think about and appreciate is that
- 20:46the medications we have available, these medications are meant to treat specific symptoms.
- 20:55We really don't have medications that are meant to treat disorder entities.
- 21:05We have medications that treat specific symptoms that may be part of a given disorder.
- 21:12So one thing that is
- 21:17often less helpful to a prescriber to hear
- 21:21is all the dynamic reasons why a therapist feels that a person is having a problem;
- 21:28family dynamics, history of trauma, you know, conflicts with a spouse, problems getting along with their peers, difficulties with schoolwork.
- 21:41Those things are important to some degree, but you have to understand that it is...
- 21:46those kind of factors don't drive medication decisions.
- 21:50What drives a medication decision really is the symptoms, and being that I'm a psychologist before I became a prescriber, I actually enjoy having these kinds of
- 22:01conversations with therapists because they're speaking my language, right?
- 22:05But something I got very used to when I was working as a psychologist and consulting a lot with medical prescribers, especially pediatricians, you know, they want a
- 22:16brief conversation that succinctly explains why you are referring someone for medications and that "why" really has to do with what symptoms do you think are the most important and
- 22:33the most impairing to the person at this time so that to treat those symptoms, we can consider a medication.
- 22:42So if we can really cut to the chase and just summarize the most salient points about how the person is functioning and what actual functional difficulties and symptoms they're
- 22:56experiencing now, that probably is the most important for a prescriber to hear.
- 23:01So now let's say you are collaboratively, with the prescriber, treating a case, the prescriber is seeing them.
- 23:14I usually see patients once a month, but I know a lot of psychiatrists and other professionals see patients less frequently, maybe a couple of times a year, right?
- 23:22But even with
- 23:24me seeing patients once a month, it's still less frequently than a therapist who usually sees them weekly, maybe once every other week.
- 23:34When we have contact in the course of the treatment, to kind of update each other on how things are going, what the prescribers look for from therapists is A)
- 23:47Keep in mind what I said before, when I prescribed this medication to treat those particular symptoms, how are those symptoms doing?
- 23:56I'm not really interested in how well their family dynamics are resolving, right?
- 24:01I'm not really interested on how well the person is getting along with their spouse.
- 24:07You know, I may be only to the extent to which that may describe some of their symptoms, right?
- 24:12But again, keep in mind that medications are really very concrete in what they're trying to do.
- 24:18So the first thing we need to hear is, I prescribed this medication to treat a few concrete symptoms.
- 24:25Have these symptoms changed?
- 24:27The second thing I really am interested in hearing is, now that I'm prescribing a medication, and of course, every medication does not only what we want it to do, but it
- 24:37also goes through
- 24:38every single compartment in the body.
- 24:40So it may have effects on other parts of the body.
- 24:44The other thing I want to do is, are there any side effects?
- 24:48Are there any changes in energy, in libido, in inability to pay attention, in sleep, in appetite, in weight?
- 25:02Are there any changes in those kinds of things?
- 25:05And I think counselors and mental health professionals who see patients on a weekly basis really are in the catbird seat to be able to collect this kind of information because
- 25:16you're seeing patients so frequently.
- 25:18So as a prescriber who may have contact with a therapist a couple of times a year, maybe to just kind of get updated, that kind of information is really helpful to me.
- 25:27It's have you seen changes in life patterns that have to do with,
- 25:33you know, with weight, with appetite, with sleep.
- 25:36Are you seeing things that could potentially be attributed to be side effects of the medications?
- 25:42So I am curious, what advice do you have for clinical counselors who are working with a client and they're using all of their superpowers and mental health tools and they're
- 25:59like, gosh, I really think that a consultation for a medication would be so supportive for you or your child or your loved one,
- 26:11and there's so much resistance against it.
- 26:13What are some of the tips that you might have for these counselors?
- 26:18One thing that I even try to communicate to some of my patients and certainly the mental health professionals I interact with...
- 26:30And this becomes especially important when you work with kids and adolescents, especially teens, right?
- 26:36Yeah.
- 26:38So, you know, I always like to kind of say somewhere
- 26:44early during the process of my interaction with them is that just because you're speaking with me does not mean you will leave my office with a prescription.
- 26:58You may, if we agree that something might be helpful to treat, if I explain the options to you and you agree that perhaps trying a medication might be a good way to address this,
- 27:13then of course, I'll be happy to write that for you.
- 27:17The main purpose of me seeing you is to see how you're doing and review options with you.
- 27:27So then you can have a better idea what your options are.
- 27:31Now, you may decide that one of my options I'm recommending is right for you and you want to try it, you may want to think about it, right?
- 27:42So that's what I would advise therapists to try to kind of encourage their clients to see, is that when you refer someone for a consultation about a medication, that's exactly what
- 27:59it is.
- 27:59It's a consultation.
- 28:01Feedback of which may be that something is recommended, but even if it is, it doesn't necessarily mean that it has to happen, that you actually have to take it;
- 28:12helping clients realize that they're in the driver's seat in the end.
- 28:17Really, it is them who will make that decision if they feel it's right for them, right?
- 28:22So a consultation is simply to review some options.
- 28:26That may help with some of the resistance.
- 28:29I love it.
- 28:30You had mentioned some of the types of resistance.
- 28:34I know in my own clinical practice, it has been anywhere from, I don't want my libido to be impacted.
- 28:41I don't wanna gain weight.
- 28:45And I tend to sit and say, gosh, well, let's kind of look at
- 28:51this. Let's look at how can we be proactive around maybe some of the possible side
- 28:56effects. But what are some of
- 28:58you know, tips that you might give clinical counselors if they're working with a client who may be resistant to a consultation for those reasons, or they're finding they are
- 29:07having some side effects and they're contemplating stopping medication for those reasons.
- 29:14So let's take the second example first, because to me that's a situation that more urgently needs to be attended to, right?
- 29:27Because it may impact the efficacy of the treatment that they are receiving.
- 29:34So I always want patients to feel that my door
- 29:40is open for them to express concerns.
- 29:44And I also want patients to appreciate that nowadays we have such a wide variety of medications for most indications.
- 29:59There's still a few areas where there's maybe not quite as many, but really for most
- 30:06of the typical types of symptoms that might be treated with medications, you know, anxiety, even manic symptoms, psychosis, ADHD symptoms.
- 30:18We really have a pretty wide choice of medications.
- 30:23And for these various medications, the side effect profiles vary.
- 30:28They're not all the same.
- 30:31They are antidepressants which affect libido.
- 30:35And to be perfectly honest with you, the kind of effect that they have on libido for some people is a problem, but for some people is actually an improvement.
- 30:45Oh, there you go.
- 30:47So one shouldn't always think of it as always being in the same box.
- 30:53And I'll be happy to tell you what I'm talking about if you want to get back to it shortly.
- 31:00But just to finish my point, there are medications that do affect libido.
- 31:04Then there are other antidepressants which do not in any way affect libido.
- 31:08It has no effect on it whatsoever.
- 31:11There are a few medications that may affect weight by increasing a person's appetite and maybe affecting their metabolism.
- 31:21But there are actually a lot of medications that don't.
- 31:23Most antidepressants, in fact, do not have weight gain associated with them.
- 31:28There are a few that do, right?
- 31:30But for someone who is very thin and not eating very well, sometimes that's actually a benefit.
- 31:37But then if you have someone who is struggling with their weight already, well, then any good prescriber would not put them on a medication that potentially can make them even
- 31:46more.
- 31:47So I guess the main point here is that not all medications have the same side effects.
- 31:58And we have so many choices of medications now that we can tailor the fit between the medication and the patient in such a way that the patient tolerates medication.
- 32:09I have one more question and then I want to open it up to the students who are here, have any questions.
- 32:14But, you know, we have seen a huge transition in the way we offer our services as providers.
- 32:22You know, especially during COVID, during the pandemic, we started seeing more telehealth.
- 32:29I know for me as a mental health professional, my practice went from brick and mortar to exclusively online and my clients became very comfortable with that.
- 32:39So I am still doing telehealth.
- 32:42I'm curious how that has impacted psychopharmacology with telehealth.
- 32:48You know, it's impacted most of healthcare.
- 32:51It's impacted a lot of medical types of services and medication management, of course, is a medical service.
- 33:01It has impacted it.
- 33:03Certainly at this point, we do far more telehealth than we did prior to COVID.
- 33:12And there are both
- 33:14national guidelines for that, as well as I think every provider has to kind of develop their own comfort zone in terms of what they're comfortable handling via telehealth versus
- 33:35in-person visits.
- 33:37In the clinic where I work,
- 33:40probably about half of the patients that we see are physically located near enough to our clinic that even though they may prefer telehealth and we may do telehealth with them
- 33:56routinely, we can ask them to come in for an in-person appointment if needed.
- 34:02So we would do that when a patient
- 34:05maybe required a medication adjustment and the medication is such that maybe a higher dose could potentially affect maybe their blood pressure or their weight or you know.
- 34:17So then we would ask a patient like this to then come in for an in-person appointment the next time so we can actually do a physical examination and assess the impact of the
- 34:28medication on the person in person.
- 34:31For some medications, even if patients are stable or showing no side effects whatsoever, my rule is that I need to see patients at least once a year in person.
- 34:43And I will do my routine check with them.
- 34:46And especially since I work so much with kids and adolescents, I'll take their height and their weight.
- 34:52I'll see how well they're developing, how well they're progressing.
- 34:56I want to make sure I always...
- 34:58compare their height and weight to appropriate charts to see whether or not the patterns are changing in terms of how they're growing.
- 35:07I always take their blood pressure and pulse.
- 35:09And that's a really important aspect to check regularly with the pediatric population because unlike for adults, when you pretty much have one standard that applies to most
- 35:22adults and maybe is altered a little bit as the person gets older,
- 35:27for kids and adolescents, the systolic, diastolic blood pressure ranges and the pulse ranges vary widely by age group.
- 35:39So I have charts and tables that I use routinely for every one of my pediatric patients to make sure that whatever medication I'm prescribing for them has not changed their blood
- 35:53pressure or pulse in any way that is now
- 35:56not within the range that is expected to be normal for their developmental level.
- 36:03So I definitely want to check things like that.
- 36:07For the half of patients that we have at the agency that are not physically located close enough for them to come for an in-person session, then we require them to either have a
- 36:20primary health care professional, a pediatrician or a PCP that they work with.
- 36:24So we will require them to have an at least annual visit with them during which their physical health is assessed.
- 36:33And then we require a copy of that assessment so that we know how they're doing.
- 36:39And for some patients that have a little more complex psychopharmacological profile, we actually
- 36:48in most areas of the state, even though they may not be close to us, they may be close enough to see another mental health prescribing professional, not on a regular basis,
- 37:00because they may not have room in their caseload to accept them as a regular patient.
- 37:04But for a one-year check, they will see them, right?
- 37:08And then they can, again, provide that information to us to make sure that they are doing okay.
- 37:13So there's really no one that we see that is exclusively telehealth, you know, for years without seeing a patient.
- 37:25At the minimum, we would have annual contact with the patients.
- 37:28Yeah, that's what I would imagine.
- 37:30I would imagine in terms of just it sounds like a good standard of care to be able to have that full physical and, you know, to kind of have an eyeball on your patient.
- 37:43And that's about to become a national guideline because even though it's been delayed in approving it because of access issues that have resulted in the implementation of this
- 38:00rule being delayed as people, providers, and areas of the country, you know,
- 38:10become better able to have least some providers for people to be able to seek that.
- 38:15But there will be a time probably in not too distant future when that will be passed as a regulation.
- 38:24That patients will need to be seen at least annually, you know, for all psychotropic medications that are handled or prescribed through telehealth.
- 38:34This is specifically being argued now for controlled substances
- 38:38but most likely will be applied for all psychotropic medications.
- 38:43And that makes perfect sense.
- 38:43Well, Raquel and Malachi have joined us from the class and I am just curious if you have any questions or thoughts or curiosities for Dr.
- 38:55Kapalka?
- 38:56What is the path like from
- 38:58someone that's in a master's program to becoming a prescriber that's not an MD or a psychiatric nurse?
- 39:07For folks that are in California, I'm sure it's different than New Mexico, but can you say anything in general about that progression to becoming a prescriber?
- 39:19It's not yet standardized across the country.
- 39:23As I mentioned before, it is only permitted now in seven states.
- 39:27And California, unfortunately, is not one of the seven yet.
- 39:30The requirements are such that to become a prescribing psychologist, first you have to become a licensed psychologist.
- 39:40So you have to have a doctorate in psychology, you have to have an internship, you have to pass the licensing examinations, whatever the requirements are to become a psychologist in
- 39:50the first place, right?
- 39:51Once you become a psychologist, then you can complete the training after you've become a psychologist, or actually now you can complete the psychopharmacology training while
- 40:05you're finishing your doctorate.
- 40:07But whether you completed it afterwards or at the same time while you were getting your doctorate, after you are a psychologist, then you have to pass another separate licensing
- 40:21examination for psychopharmacology.
- 40:24And then every state has essentially an equivalent of a residency in a medical setting that has to be done.
- 40:36The length of it and who the specific supervisors can be very state to state.
- 40:43But the way to think about it is there is, it's about probably close to another year of now an experience in a medical setting where you're exposed to medications and you weigh
- 40:56in on medication decisions, even though you're not prescribing yet, but you're kind of doing it under supervision.
- 41:03And that's sort of
- 41:05another internship, just like psychologists have to do an internship before they become a psychologist.
- 41:11This is another form of like an internship or residency that's now specifically psychopharmacology-oriented that states require before you can get your prescribing
- 41:22license.
- 41:23And then for most states, you get your conditional prescribing license;
- 41:29now you can prescribe, but you still have to have a supervisor with whom you're reviewing cases and that person is ultimately responsible for what you do.
- 41:36And then after what usually is a two-year conditional period, then your work is once again reviewed.
- 41:43The supervisor has to release you as being ready for independent practice.
- 41:48And that's when you would become an independently practicing prescribing psychologist.
- 41:53Thank you for that.
- 41:54Yeah, that's really helpful.
- 41:55The other question I had was, I'm interested in psychedelic medicine, how that's taking hold in this country.
- 42:06I know it's very limiting.
- 42:07There's still limited research and there needs to be more, but I know that research universities like Johns Hopkins, have a
- 42:18psychedelic research lab and they're able to treat volunteer patients with this medication.
- 42:25And I'm just wondering about, you know, whether that'll ever become more than something specific to a few big colleges and universities.
- 42:35You know, this area has generated a lot of interest with some steps forward and a few setbacks.
- 42:49Some of the psychedelic medications
- 42:52are not on FDA Schedule 1, which means that even though they're not FDA-approved for use as psychotropic, they can be used as psychotropic.
- 43:06A good example is ketamine.
- 43:08There's a version of ketamine that is approved specifically for very specific circumstances for where
- 43:20it can be used for depression.
- 43:22Other forms of ketamine can be used even though there's some regulations around them, but they're legal to be used for depression and in fact are being used by some prescribers.
- 43:35With the psychedelics, a major obstacle has to do with the fact that so many psychedelics are currently on Schedule 1
- 43:47of the FDA, which means no medicinal approved use, you know, for any purpose and presumably sufficient danger to restrict its use for any purpose at this time.
- 44:02So for those kinds of substances, the research centers have to apply for a waiver from the FDA to be able to do research with those substances.
- 44:14So this is why right now a lot of that use is limited to these big centers because they need waivers, you know, to be able to do that.
- 44:25We've had some developments with marijuana, right?
- 44:31So if these substances,
- 44:35even if they do not become yet approved as psychopharmacological treatment for these conditions, if they're removed from Schedule 1, then that will eliminate a lot of the
- 44:48limitations.
- 44:48As long as they're on Schedule 1, those obstacles will remain.
- 44:53Unfortunately, there's not much that can be done about that.
- 44:56Raquel, do you have any questions or thoughts or...?
- 45:00I was curious to hear your thoughts on any upcoming trends, like changes in the space that you think are good to keep an eye on.
- 45:09in psychotropic medications or any area of psychotropic medications or...?
- 45:15I guess psychotropic medications in general, but I'm also interested in like kind of alternative sides to potentially like
- 45:22ketamine treatments, but also like TMS is another one that I'm pretty familiar with, just like in general within the space.
- 45:29You know, it's interesting because TMS is a growing area.
- 45:36Its use for depression is relatively well-established now.
- 45:44There have been other
- 45:48uses investigated to things like Tourette's, even for ADHD.
- 45:52There are devices now that are available to actually improve a person's sleep, which is kind of version of TMS.
- 46:01So there are continued developments with that.
- 46:06With psychotropics, I have to tell you one thing:
- 46:10It is incredibly expensive in the US to bring a medication to market.
- 46:17It's currently estimated that it's between one and two billion dollars per drug to bring it to market.
- 46:28Rarely less if the drug is really expedited, sometimes even more, right?
- 46:36So pharmaceutical companies, first and foremost, they are businesses.
- 46:42Corporations that have to answer to stockholders.
- 46:46While they may have some concerns about how much good they're, you know, whether the potential benefit to society of what they're doing, that's really not their primary
- 46:55concern.
- 46:56Their primary concern is return on their investment and keeping their investors and their stockholders happy and the company, you know, growing in its stock value, right?
- 47:11So with that being the case, when new medications are being developed, pharmaceutical companies always think about if we invest a certain amount of money into a compound, how
- 47:27big of a market share are we going to have?
- 47:30And just how well is this product going to sell when it, let's say it
- 47:36does go all the way and we spend all that money, FDA approves it, as in approves the medication, and we can now market it...
- 47:45What are the sales going to be like?
- 47:48And unfortunately, the answer to it is that the sales for psychotropics by comparison are really minuscule in terms of the profit they bring to a company as compared to sales for,
- 48:03for example, the GLP-1 drugs, right?
- 48:08So companies have a lot of incentive to bring another GLP-1 drug, especially one that's going to be oral, right?
- 48:18Huge market in that.
- 48:20And the next billion and billion upon billion worth company is going to be the one who does that rather than brings another psychotropic to the market.
- 48:30And so that really stifles, I think, development in psychotropics.
- 48:37And the other thing to kind of think about too is that we actually have less psychotropics in the US than in many European countries.
- 48:45And the reason for that is because the FDA bar is so high, so expensive, and also their safety requirements are pretty high to be able for them to approve the medication.
- 48:56So then, as has happened many, many times, many psychotropics become available for use in other markets before they ever come to the US.
- 49:09So if you're really interested in some of the newer psychotropics that come to the market, and there are a few that are being used elsewhere and not in the US, the first place
- 49:20you're probably going to see them will be somewhere in Europe or in Asia.
- 49:24Interesting.
- 49:25Thank you for that.
- 49:26That is all such great insight.
- 49:28I think it's really important to recognize the positioning of pharma within the global economy.
- 49:36But yeah, I appreciate that.
- 49:38Thank you.
- 49:39Dr.
- 49:39Kapalka, is it possible that the students might be able to reach out to you if they have questions?
- 49:45It's george.kapalka, K-A-P-A-L-K-A at alliant.edu.
- 49:54And yes, please feel free.
- 49:56My door is always open.
- 49:58I really enjoy interacting with students about these issues.
- 50:03It's a topic I enjoy discussing.
- 50:05Well, Dr.
- 50:06Kapalka, thank you so very, very much for taking the time.
- 50:10I've learned so much and you're such a great resource for us at Alliant.
- 50:14Malachi and Raquel, thank you for popping in.
- 50:16Hopefully your colleagues will also benefit from the wisdom of our wonderful colleague here.